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ABSTRACT 
 
Tumor suppressor genes, p15INK4B and p16INK4A p14ARF, are the most 
frequently silenced genes in human cancers (Kim and Sharpless, 2006) 
because they represent a biological barrier to transformation (Skalska et al., 
2013). Frequently, silencing is the result of DNA methylation of promoter 
regions, and to date, the precise mechanism is not known.  
Here, we present evidence that DNA methylation is associated with DNA 
damage caused by collisions between DNA and RNA polymerases near the 
transcription start sites. Inhibition of replication or transcription greatly 
reduces DNA damage and ultimately, local CpG methylation. 
This mechanism generates in vivo many variants (alleles) of p15INK4B 
p16INK4A and p14ARF genes, which differ only by the occurrence of 
methylated CpG within the sequence (epialleles). If some epialleles are 
positively selected, we expect to find them amplified in a complex population 
of proliferating cells. We have tested this notion by systematically 
investigating: 1. the configuration of methylated CpGs in each p16INK4A 
sequenced molecule (epiallele) and; 2. the frequency of families of epialleles 
during the progression of acute myeloid leukemia (AML) in cells from the 
bone marrow or the blood of three patients.  
  
The relevant results can be summarized as follows: 1. The epialleles, defined 
by unique methylation profiles, were stable and patient-specific. 2. The 
epialleles displayed gene specific methylation signatures and were 
somatically inherited; 3. Some epialleles were eliminated by the 
demethylating therapy (5-AzadC, Vidaza®), others were resistant or 
amplified by the demethylating drug and their frequency increased before and 
during the disease relapse; 4. The presence of high levels of epialleles after 
the therapy predicted the chemoresistance; 5. The epialleles of another 
suppressor, p21/WAF, in the same patients, did not evolve and remained 
stable throughout the progression of the disease; 6. Specific p16INK4A gene 
CpGs function as “seeds” for further methylation.  
 
Collectively, these data indicate: 1. An epigenetic mechanism driving the 
evolution of AML by dynamic methylation of alleles of p16INK4A suppressor 
gene; 2. The methylation changes during AML progression may be facilitated 
by DNA damage; 3. The distribution and the frequency of families of 
p16INK4A epialleles overtime accurately describe the evolution of myeloid 
acute leukemia. 
  
  
 	 7	
1. INTRODUCTION 
1.1 CYCLIN-DEPENDENT KINASE INHIBITORS 
 
1.1.1 MEMBERS AND THEIRE FUNCTION 
 
Cyclin dependent kinase inhibitors (CDKIs) are proteins involved in the 
control of cell cycle progression. They inhibit the enzymatic activity of 
cyclin-dependent kinase (CDK) by binding. 
CDKIs are divided into two major groups on the basis of their structural 
characteristics and specificity of binding. 
One is composed by INK4 (inhibitor of CDK4) family comprising p16INK4A 
p15INK4B p18INK4C p19INK4D, which inhibit the complex cyclin D-CDK4/6 
(Sànchez-Beato et al., 1997). The other family, Cip/Kip, is composed by 
p21CIP1/WAF1 p27KIP1 p57KIP2 which inhibit a broad spectrum of cyclin-CDK 
complexes (Starostina and Kipreos, 2012). 
 
 
Figure 1: Cell Cycle Progression. CDK and cyclins promote the progression through the cell cycle. 
Different CDKIs are expressed at different phases of the cell cycle. 
 
The expression of these genes is frequently inhibited in human cancers. 
Promoter hypermethylation, point mutations, deletion are responsible for 
silencing of these genes in more than 90% of human cancers. In the last 
decades, researchers are focusing their attention on cell cycle regulators as 
targets for the development of new molecules to cure cancer (Otto and 
Sicinski, 2017). 
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1.1.2 INK4 FAMILY MEMBERS 
 
INK4 family members are highly conserved in evolution and are involved in 
cell cycle control at different levels. 
p15INK4Band p16INK4A act as peculiar CDK4/6 inhibitors in the retinoblastoma 
pathway; their inactivation allows cells to escape the G1 restriction point in 
the cell cycle (Ferreira et al., 2015). p19INK4D binds and promotes MDM2 
degradation, a protein involved in retinoblastoma and p53 pathways (Zhang 
et al., 1998).  
The INK4 family members are clustered in a small region of chromosome 9 
(9p21) (Fig. 2). The unusual evolution of this locus can be explained by the 
advantage to coordinate the transcriptional regulation of several cell cycle 
regulators clustered in the same DNA segment with the same chromatin-
remodeling events. Repression by Polycomb (PcG) complexes is one way to 
silence the genes in the INK4 locus through the induction of local 
H3K27methylation. Loss of PcG genes reveals a defect in hematopoiesis and 
other disorders in part due to de-repression of INK4/Arf locus (Gil and 
Peters, 2006). If silencing INK4 genes is a rather simple process, their 
positive regulation is rather complex, since it is controlled by different 
agents, which act on different members of the gene family. Ionizing 
radiation, DNA damage (Lafargue et al., 2017), ultraviolet irradiation, 
oxidative stress response (Jenkins et al., 2011), replicative senescence 
(Helman et al., 2016) activate INK4a. Mitogen agents such as RAS and 
MYC proteins activate both INK4a and ARF (Gil and Peters, 2006) while 
INK4b activation depends mostly on Transforming growth factor β (TGFβ) 
signaling (Rich et al., 1999).  
 
Figure 2: Schematic Representation Of INK4-ARF Locus. Bar (colored vertical lines) indicates 
coding exons of the genes separated by introns (horizontal black lines). Exons E1 and E2 of INK4a 
(light green) are translated in an alternative reading frame in order to synthesize p19ARF or p14ARF 
human protein. INK4a-b genes suppress CDK4/6 to activate Retinoblastoma (Rb) pathway and inhibit 
cell cycle progression; p14ARF directly suppresses Mdm2 to activate p53 and negatively regulates cell 
cycle progression. ANRIL is a long non-coding RNA transcribed from an undefined promoter in an 
antisense direction relative to INK4-ARF genes. Its products are spliced and putative exons indicated 
by the red bar.  
Adapted from Sherr, C. J. 2012. 1:731-741.  
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1.1.3 CIP/KIP FAMILY MEMBERS 
 
Cip/Kip family members act at the G1/S and G2/M checkpoints. Initially, all 
family members were considered negative regulators of the cell cycle (Harper 
et al., 1993). Eventually, new data demonstrated that cytoplasmic p21 and 
p27 were also able, in contrast with their nuclear role, to mediate the 
assembly and nuclear import of CDK4/6-cyclin D (Cheng et al., 1999). 
Therefore, p21 and p27 activity is influenced by their localization. 
 
 
Figure 3: Different Action Mediated By CIP/KIP Family Members in the Nucleus and in the  
Cytoplasm. In the nucleus CIP/KIP family members act as cyclin-CDK inhibitors, while in the 
cytoplasm they regulate actin reorganization by inhibiting Rho-Rock-Limk pathway. The mechanism 
underlying p21 export to the cytoplasm is still unknown. p57 inhibits the function of LIMK preventing 
its binding to cofilin. 
Adapted from Denicourt 2004;18(8):851-5. 
 
Overall, these genes are involved in the control of cell proliferation during 
development, differentiation and response to different types of cellular 
stresses. However, selective pathways activate each member of the family.  
The p21 protein, for example, is a well-characterized transcriptional target of 
p53 and it mediates DNA damage-induced cell cycle arrest in G1 and G2 
(Gartel and Tyner, 1999). On the other hand, p27 maintains the cells in a 
quiescent state. Cell cycle is accompanied by down-regulation of the protein 
(Gartel and Radhakrishnan, 2005). Also, p57 influences embryonic 
development. 
In conclusion, the Cip/Kip family members are essential for cell growth and 
survival, because knockout mouse models for each member show increase of 
body size and hyperplasia or delayed differentiation (Besson et al., 2008).  
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1.1.4 THE INK4 LOCUS AFFECTS CELL FATE 
  
INK4/Arf locus encodes three potent inhibitors of proliferation. Silencing of 
the locus is required to induce pluripotent stem cells (iPS) or to support 
proliferation of embryonic stem (ES) cells (Li et al., 2009). On the other 
hand, p16Ink4a protein is a well-known biomarker of aging in mammalian 
cell. Accelerated aging can be rescued in T or B lymphocytes by a deletion of 
p16Ink4a; however, it should be pointed out that loss p16Ink4a leads to B-
cell neoplasia (Liu et al., 2011). Methylation of INK4/Arf locus is found in 
several human cancers (Serrano et al., 1996). Also, germ line mutations of 
p16INK4a are associated with malignant melanoma and pancreatic cancer 
(Whelan et al., 1995). Taken together, these data suggest that CDKN2A/B 
genes are involved in the modulation of the cell life balance: proliferation or 
senescence. Overexpression or down-regulation of these genes can result in 
cellular death or exit from the cycle. While CDKN2A/B overexpression 
commits cells to premature aging, down-regulation of the expression of these 
genes promotes cancer progression and acquisition of immortality (LaPak 
and Burd, 2014). The expression of INK4/Arf locus genes acts as a barrier to 
transformation by preventing the progression of damaged DNA harboring 
cells into the replication process. This inhibits the spreading of deregulation 
and damage to daughter cells. This circuitry is the main barrier to 
transformation of a cell. Only cells that inhibit the expression of INK4/Arf 
locus genes are able to escape apoptosis and exit from the cell cycle 
(senescence). Since CDKN2A/B genes are clustered, damage occurring at the 
INK4 locus may deregulate most or all of them in few steps, providing to a 
normal cell the chance to overcome the damage and become immortal  
(Sherr, 2012). 
 
1.2 THE SENESCENCE IS A BARRIER TO TRANSFORMATION   
 
Senescence in humans and mice 
 
Mice and humans have in common systemic physiology, the number of 
organs, many genes and this is the reason why in science mouse models are 
extensively used to study human diseases (Demetrius, 2005). However there 
is substantial evidence that cancer is driven by different signaling pathways 
in humans and mice. 
The human life spans is 30-50 time longer than mice, suggesting that human 
cells undergo about 105 cell divisions compared to the mouse. Since the 
chance to develop a tumor is positively correlated to the number of mitotic 
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divisions, humans should have higher incidence of cancer compared to mice. 
This notion does not reflect the reality. 
Humans and mice differ in cancer susceptibility, spectrum of age related 
cancer, telomere length, ability to undergo spontaneous cells immortalization. 
These differences derive from different pathways implicated in cellular 
immortalization. Mouse embryonic fibroblasts, in vitro, became immortalized 
spontaneously once telomerase activity decreases, indicating this event as the 
major responsible for transformation. Human fibroblasts instead, in vitro, 
after a definite number of replications, enter a phase called replicative 
senescence. During this phase telomerase activity decreases and the telomere 
became shorter, activating a DNA damage response (DDR). A single 
surviving clone can emerge at low frequency and eventually can became 
immortal. In conclusion, human cells have to cross two barriers (senescence 
and telomere shortening) before becoming immortalized. In humans, the 
driver gene of senescence is p16INK4A; p16INK4A silencing and inactivation 
provide a proliferative selective advantage and permit the exit from 
senescence (Rangarajan and Weinber, 2003).  
  
1.3 DNA METHYLATION AND SILENCING OF INK4-ARF LOCUS 
GENES 
 
1.3.1 INK4-ARF LOCUS SILENCING IN HUMAN AND MOUSE  
 
Down regulation of tumor suppressor genes is a prerequisite for cancer 
progression (Lee and Muller, 2010). The loss of one allele does not necessary 
indicate a pre-cancerous condition.  The biological phenomenon called “loss 
of heterozygosity” (LOH) is responsible for the inactivation of the remaining 
copy of tumor suppressor genes and this event is a prerequisite for cancer 
development and/or progression. It can occur by mitotic non-disjunction 
or/and duplication (Thiagalingam et al., 2001); mitotic recombination (Luo et 
al., 2000); gene conversion (Zhang et al., 2006); point mutation and allele 
deletion (Miyake et al., 1994) and silencing (Kazanets et al., 2016). 
Gene promoter hypermethylation and silencing are common events leading to 
dys-regulation of gene expression in human cancers. Several studies reported 
a large number of human genes regulated by DNA methylation; the table 
below shows some examples. 
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Table I: Selected Genes That Undergo CpG Island Hypermethylation In Human Cancer. 
Adapted from Esteller 2002;21(35):5427-40. 
 
Genetically engineered mouse models (GEMMs) are extensively used to 
study human cancer biology, but they cannot be always compared to human 
cancer. 
Specific CpG island methylation patterns characterize different types of 
tumor genes in humans. There is a substantial difference in some CpG islands 
methylation patterns of genes involved in cancer progression between 
humans and GEMMs. In the Eµ-Myc mouse model of Burkitt lymphoma was 
reported higher DNA methylation due to high expression of DNMT3B7, a 
truncated isoform of DNMT3B, but this trait is not cancer specific (Shah et 
al., 2010). 
DNA promoter hypermethylation in cancer mouse cells induced by a 
previous inflammatory state better describes human tumorigenesis than 
examples in GEMMs induced-phenotypes driven by oncogenes (Diede et al., 
2013).  
Nowadays the number of silenced human genes by promoter 
hypermethylation is still growing, but the mechanism is still unknown. 
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1.3.2 INK4-ARF LOCUS SILENCING IS A COMMON EVENT IN 
ACUTE LEUKEMIA 
 
The negative regulation of cell cycle mediate by p15INK4B and p16INK4A p14ARF 
in physiological condition is the reason explaining the high rate of silencing 
of these genes during cancer progression (Christiansen et al., 2003). 
The p15INK4B gene is an effector of antimitotic signaling induced by TGF-β, 
which is involved in the regulation of hematopoiesis. Specifically, in the 
myeloid lineage p15INK4B expression cannot be detected in CD34+ progenitor 
cells but only during terminal differentiation to granulocyte (Teofili et al., 
2001). The p16INK4A gene, in an opposite trend, is expressed in CD34+ cells, 
but suppressed during the terminal differentiation of the myeloid lineage 
(Furukawa et al., 2000). 
Point mutations are rare in hematopoietic diseases, while homozygous 
deletion or gene silencing by promoter hypermethylation at CpG sites are 
common events, especially in acute myeloid leukemia and in myelodysplastic 
syndrome (Drexler, 1998). These abnormalities are considered as early events 
in leukemogenesis (Christiansen et al., 2003). Both, p15INK4B and p16INK4A 
genes are silenced in leukemia, p15INK4B promoter is hypermethylated  during 
the initial steps of cancer progression, while p16INK4A gene methylation is 
acquired later, during clonal evolution (Chim et al.,  2001). 
 
1.4 DNA METHYLATION AND CANCER PROGRESSION 
 
1.4.1 GENETIC AND EPIGENETIC CHANGES IN CANCER 
 
Cancer is the result of genomic imbalance and epigenetic modifications 
leading to cell immortalization. 
A common characteristic of genetic and epigenetic modifications is their 
hereditability. Genetically and epigenetically-modified somatic cells can 
transfer the information to daughter cells which acquire the ability to expand 
to one or more clones, which are positively selected by their high replication 
rate (Sadikovic et al., 2008). 
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Figure 4: Co-evolution Of Genetic And Epigenetic Changes. Genetic and epigenetic changes 
together increase the potential and drive  tumor evolution. 
Adapted from Sadikovic et al., 2008;doi:10.2174/138920208785699580. 
 
1.4.2 THE EPIGENOME PLAYS A KEY ROLE IN CANCER 
EVOLUTION 
 
Tumor heterogeneity is one of the main causes of failure of cancer therapies, 
and chemo-resistance. Tumor progression is a dynamic event driven by 
genetic and epigenetic modifications in somatic cells (Urbach et al., 2012). Is 
still unknown the cause-effect relationship between genetic and epigenetic 
modification during cancer progression, however it is a fact that the same 
genetic mutation may cause different phenotypes (Li et al., 2016). 
DNA methylation, as stable and inherited epigenetic trait, is extremely 
polymorphic in somatic cells and is generated by alleles differing only for the 
location of methylated CpGs. These variants are named epialleles.  
These epialleles are polymorphic and may represent a “cellular barcode” that 
can be used to track specific cells in complex populations (Landan et al., 
2012; Russo et al., 2016).   
 	 15	
2.  
3. AIM OF THE STUDY 
 
Cancer is a dynamic disease. During neoplastic progression, tumor cells gain 
mutations and modify their epigenetic profiles to increase their fitness. 
Epigenetic and genetic clonal heterogeneity is tightly associated with 
chemoresistance and evolution of tumor cells. 
The progressive silencing of p15INK4B and p16INK4A p14ARF oncosoppressor 
genes confers a selective advantage to tumor cells as shown by the high 
frequency of transcriptional inactivation of these genes in most types of 
cancer. 
 
The main goals of this study are: 
-The mechanism(s) responsible for the high frequency of methylation of 
p15INK4B and p16INK4A p14ARF suppressor genes. 
-The analysis of methylated alleles of p16INK4A during evolution of acute 
myeloid leukemia in human patients. 
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3. MATERIAL AND METHODS 
 
3.1 CELL CULTURE AND DRUGS TREATHMENT 
 
HeLa cells were cultured in DMEM medium with 4,5g/L D-glucose and 
Pyruvate (Gibco, Carlsbad, CA, USA) complemented with 100u/mL of 
penicillin and 100µg/mL of streptomycin (Gibco, Carlsbad, CA, USA), 2mM 
L-glutamine (Gibco, Carlsbad, CA, USA), in presence or absence of 10% of 
FBS (South America origin, Brazil, Invitrogen, Rockville, MD, USA). All 
culture were maintained in 37 °C at 5% CO2 humidified atmosphere. 
All drugs treatment were administered to adherent cells and dissolved in 
complete or medium without FBS. 
Aphidicolin (Sigma-Aldrich, St Louis, MO, USA) at final concentration of 
1µg/mL and α-amanitine (Sigma-Aldrich, St Louis, MO, USA) at final 
concentration of 2,5µM, were added to cell culture medium. Etoposide 
(Sigma-Aldrich, St Louis, MO, USA) was added to cells culture medium for 
30 minutes at 25µM final concentration.  
3.2 DNA AND RNA EXTRACTION 
 
DNA was extracted from cell pellets, purified by phenol/chloroform/isoamyl 
alcohol extraction and precipitated by ethanol. The pellet was dissolved in 
Tris-EDTA buffer (Sigma-Aldrich, St Louis, MO, USA). 
Total mRNAs was extracted using TRI-REAGENT® (Sigma-Aldrich, St 
Louis, MO, USA) solution, according to the manufacturer’s instruction. The 
nucleic acid quality was tested by using NanoDrop 2000 (Thermo Scientific) 
and the absorbance ratio was measured at 260/230 and 260/280 um. 
 
3.3 cDNA AND REAL TIME PCR 
   
One microgram of total mRNAs was reverse transcribed using SensiFAST® 
cDNA Synthesis Kit (Bioline, London, UK) according to the manufacturer’s 
instruction, dissolved in 20µL of nuclease-free water (Qiagen, Hilden, 
Germany). All PCR real time experiments were performed three times on a 
7500 Real Times PCR System (Applied Biosystems, Foster City, CA, USA) 
using the SYBR® Green-detection system (Roche, Penzberg, Germany). The 
complete list of oligonucleotides used is reported in Table II. 
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3.4 PROTEIN EXTRACTION AND WESTERN BLOT ANALYSIS 
 
Cells lysis was carried out using RIPA-Buffer (Sigma-Aldrich, St Louis, MO, 
USA) and protein concentration was determined by Bio-Rad protein assay. 
Equal amounts of denatured proteins were subjects to SDS PAGE 10% 
polyacrylamide gel. Proteins were visualized using ECL substrate 
(Euroclone, Milano, Italy) and ECL chemiluminescence film (Fujifilm®). 
Phospho S1981 ATM (Abcam, Cambridge, UK) normalized using as 
reference total ATM (Abcam, Cambridge, UK) protein and normalized to β-
actin (Sigma-Aldrich, St Louis, MO, USA) as loading control.   Western blot 
bands were normalized to β-actin with Image J software. 
3.5 CHROMATIN IMMUNOPRECIPITATION 
 
HeLa cells were starved, as indicated in the legend of the Figures. Cells were 
fixed using formaldehyde at final concentration of 1%. The reaction was 
quenched by adding 125mM glycine. 
Nuclei were isolated using a lysis buffer (Proteinase inhibitor cocktail, 
10 mM Tris pH 8.0, 10 mM NaCl, NP40 0,2%, PMSF 1%) and fragmented 
by sonication (Bioruptor® Pico Sonicator, Diagenode, Ougrèe, Belgium). An 
aliquot of each sample was used as INPUT, and the remaining fraction was 
precipitated using phosphor-γH2AX antibody (Cell Signaling, Danvers, MA, 
USA). All samples were processed using a ChIP assay kit (Upstate 
Biotechnology, Lake Placid, NY, USA) according to the manufacturer’s 
instructions. Real Time PCR was used to quantify the immune-precipitated 
DNA and the data were normalized to the input. All values represent the 
average of at least three independent experiments. 
3.6 FLOW CYTOMETRY ANALYSIS  
 
Cells were harvested and fixed with 70% cold ethanol and PBS solution in a 
ratio 9:1 at 4°C overnight. After was in PBS, the cells were incubated in 500 
µl of staining solution (20 µg/mL propidium iodide; 0,1-0,2 mg/mL RNaseA; 
TRITON 0,1%) at room temperature for 30 min. The samples were analyzed 
with the FACSCAN (BD, Heidelberg, Germany) and the cell cycle 
distribution was analyzed with the software WINMDI. 
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3.7 MeDIP ASSAY 
 
Cells were treated as indicated in legends of the Figures. A total of 
~2,6 × 106 cells were harvested and genomic DNA extracted as described 
above. 7,7 µg of total genomic DNA was digested in 100 µl for 16 h AT 37° 
with restriction endonuclease mix containing 30 U each of Eco RI, Hind III, 
Hpa II (Roche, Penzberg, Germany), phenol/chloroform extracted, ethanol 
precipitated and re-suspended in 50 µl of TE buffer (10 mM Tris pH 8.0, 
1 mM EDTA). An aliquot (1/10) of digested DNA was used as input control 
to determine DNA concentration and digestion efficiency. Remaining DNA 
was diluted in 500 µl of immunoprecipitation buffer (0.15% SDS, 1% Triton 
X-100, 150 mM NaCl, 1 mM EDTA pH 8.0, 0.5 mM EGTA pH 8.0, 10 mM 
Tris pH 8.0, 0.1% BSA, 7 mM NaOH) and incubated at 95°C for 10 min 
before the immunoprecipitation with 5 µg of 5-methyl cytosine antibody 
(Abcam, Cambridge, UK). As a control, 5 µg of normal mouse IgG (Santa 
Cruz, Dallas, TX, USA) was included. 
Samples were, then, extracted with phenol-chloroform-isoamyl alcohol, 
ethanol precipitated and re-suspended in TE buffer. All samples were 
analyzed by Real Time PCR. 
 
3.8 BISULFITE TREATMENT AND AMPLICON LIBRARY 
PREPARATION 
 
We converted 2 µg of genomic DNA in genomic bisulfite DNA using 
according EZ DNA Methylation Kit (Zymo Research, Irvine, CA, USA) and 
eluted in 50µl of d-H2O following the manufacturer’s instruction.  An 
amplicon library of bisulfite treated DNA was generated performing a double 
step PCR. In the first PCR reaction, fragment of size about 500-550bp were 
amplified. The second PCR reaction is performed in order to add a nucleotide 
tag, using specific primers containing multiplexing indices and Illumina® 
sequencing adapters. The first PCR was performed using a “FastStart High 
Fidelity PCR System”(Roche, Penzberg, Germany) at the following thermo 
cycle conditions: one cycle at 95°C for 2 min followed by 30 cycles at 95°C 
for 30 sec, at TM 50°C for 45 sec, at 72°C for 60 sec, followed by a final 
extension step at 72°C for 10 min. Reactions were performed in 20 µl total 
volumes: 2 µl 10x reaction buffer, 1 µl of 10 mM dNTP mix, 1 µl of 4 µM 
forward and reverse primers, 3.6 µl MgCl2 25 mM, 2-4 µl bisulfite template 
DNA, 0.25 µl FastStart Taq, and d-H2O up to a final volume of 30 µl. Five 
microliters of the first PCRs were used to check the product size on 1.5% 
agarose gel.  
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A purification step using 20µl of AMPure purification magnetic Beads 
(Beckman-Coulter, Brea, CA, USA) following the manufacturer's 
instructions, was performed before the second PCR to eliminate small DNA 
fragments. The second PCR was performed in a 50 µl final volume: 5 µl 10x 
reaction buffer, 2.5 µl of 10 mM dNTP mix, 5 µl forward and reverse 
“Nextera XT” primers (Illumina, SanDiego, CA, USA), 6 µl MgCl2 25 mM, 
5 µl of first PCR product, 0.4 µl FastStart Taq, and d-H2O up to a final 
volume of 50 µl. Thermo-cycle settings were: one cycle at 95°C for 2 min 
followed by 8 cycles at 95°C 30s, 55°C for 40 sec, 72°C for 40 sec, followed 
by a final extension step at 72°C for 10 min. 
 
3.9 SEQUENCE ANALYSIS 
 
All paired–ends reads (minimum overlapping residue = 40) obtained from 
Illumina Miseq sequencer platform were matched together using PEAR tool. 
The quality filtered was obtained using as threshold a mean of PHREAD 
score at least 33. FASTQ assembled reads were converted to FASTA format 
using PRINSEQ tool. To analyze the methylation status of each amplicon 
was used a pipeline software (Amplimethprofiler) freely available at 
https://sourceforge.net/projects/amplimethprofiler (Scala, 2016). 
3.10 ANTIBODIES 
 
The following antibodies were used in this study: Anti-5-methylcytosine 
ab10805 (Abcam); Anti-ATM (phosphor S1981) ab81292 (Abcam); Anti-
ATM ab199726 (Abcam); Anti-gamma H2A.X (phospho S139) ab2893 
(Abcam); Anti-beta Actin sc-47778 (Santa Cruz Biotechnology); Normal 
mouse IgG sc-2025 (Santa Cruz Biotechnology). 
 
3.11 STATISTICAL ANALYSIS 
 
All data are presented as mean ± standard deviation in at least three 
experiments in triplicate (n=9 or greater). Statistical significance between 
groups was determined using Student’s t test on Excel program (matched 
pairs test or unmatched test were used as indicated in figure legends).  
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TABLE II 
 Primers for mRNA 
 
18s fw 
 
5’-GCG CTA CAC TGA CTG GCT C-3’ 
18s rv 5’-CAT CCA ATC GGT AGT AGC GAC-3’ 
CDKN2A fw 5’-AGT TAC GGT CGG AGG CCG AT-3’ 
CDKN2A rv 5’-TGG AGC AGC AGC AGC TCC-3’ 
CDKN2B fw 5’-ACT AGT GGA GAA GGT GCG ACA-3’ 
CDKN2B rv 5’-TAG GTT CCA GCC CCG ATC C-3’ 
CDKN2A-ARF fw 5’-CTA CTG AGG AGC CAG CGT CTA-3’ 
CDKN2A-ARF rv 5’-CTG CCC ATC ATC ATG ACC T-3’ 
CDKN1A fw 5’-GCT GGT GGC TAT TTT GTC CT-3’ 
CDKN1A rv 5’-CAT GGG TTC TGA CGG ACA T-3’ 
α-SMA fw 5’-CTG TTC CAG CCA TCC TTC AT-3’ 
α-SMA rv 5’-TCA TGA TGC TGT TGT AGG TGG T-3’ 
 
 Primers for ChIP 
CDKN2A fw 5’-AGA GTA GTC AAC GCA GTG TC-3’ 
CDKN2A rv 5’-TGA GAG CTG ATC CCA GTC TTG-3’ 
CDKN2B fw 5’-ATT AGC CTT GGC TTT ACT GG-3’ 
CDKN2B rv 5’-GGC AAA GAA TTC CGT TTT CAG C-3’ 
CDKN2A-ARF fw 5’-GAG CCG TTC CGA GAT CTT GG-3’ 
CDKN2A-ARF rv 5’-CCC CTT AAC TGC AGA CTG G-3’ 
CDKN1A fw 5’-ATG TGT CCA GCG CAC CAA CG-3’ 
CDKN1A rv 5’-AGC TCA GCG CGG CCC TGA TAT AC-3’ 
 
 Primers for Bisulfite 
CDKN2A fw 5’-TTT TTA GAG GAT TTG AGG GAT AGG-3’ 
CDKN2A rv 5’-CTA CCT AAT TCC AAT TCC CCT ACA AAC-3’ 
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4. RESULTS 
4.1 TRANSCRIPTIONAL REGULATION OF CDKN2A/B GENES 
DURING CELL CYCLE 
 
CDKN2A/B suppressor genes are located on chromosome 9p21 in INK4-
ARF locus. These genes are transcriptionally repressed in many tumors but 
the biological mechanism leading to silencing is not known. 
To dissect the mechanism of transcriptional silencing of these genes, we 
focused our efforts on the regulation of p15INK4B and p16INK4A p14ARF genes 
during cell cycle progression. 
Hela cells were used as model system to investigate the regulation of 
expression of p15INK4B p16INK4A p14ARF during cell cycle progression. We 
starved HeLa cells from fetal bovine serum (FBS) for several periods of time 
and  serum was re-added to allow the entry of the cells into cycle. 
The mRNA analysis by qPCR of p15INK4B p16INK4A p14ARF and 
p21/CDKN1A genes is shown in Fig. 5. The mRNAs levels of p15INK4B 
p16INK4A and p14ARF increased after 2 hours of starvation. Under these 
culture conditions p21/CDKN1A mRNA did not change significantly. 
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Figure 5: Induction of p15INK4B p16INK4A and p14ARF mRNA By Serum Starvation.  Analysis of 
CDKN2A-B and control genes by RT-PCR. Cells were subjected to FBS starvation for 2 h. The serum 
was added for 6 h and total RNA extracted and analyzed by qPCR with the appropriate primers 
indicated in M&M. Each column represents the average value of experiments in triplicate  (2 technical 
and 1 biological replicates).  
 
The data shown in Fig. 5 suggest that p15INK4B p16INK4A and p14ARF 
expression is higher in G0 and early G1 cells and is repressed in S phase. To 
demonstrate that the expression of INK4-ARF locus genes is regulated during 
the phases of the cell cycle, we performed a cell cycle analysis by flow 
cytometry. As for mRNA analysis, cells were starved and re-induced to entry 
the cycle by adding the serum for different periods of time (2 and 4 h).  
Figure 6 shows that after 2 h starvation the majority of cells are in G0/G1 
phase and this corresponds to the higher expression levels of p15INK4B 
p16INK4A and p14ARF. Induction of cell cycle entry reduces dramatically 
p15INK4B p16INK4A and p14ARF expression. Under the same conditions p21 
mRNA levels do not change (Fig. 5). 
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Figure 6:  Cell Cycle Progression of Hela Cells Before, During And After Serum Starvation. 
The experiment was performed as described in figure 5, cells were fixed and stained with propidium 
iodide prior to analysis in a FACSCAN. The graphs show the relative DNA content (x axis) versus 
cell number (y axis). Red numbers indicate the percent of cells in each cell cycle step. Each 
experiment was performed at least in triplicate. 
We conclude that serum starvation for 2 hour is able to induce p15INK4B 
p16INK4A p14ARF and synchronize the cells in G0/G1.  
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4.2 DNA DAMAGE SIGNATURES AT CDKN2A-B GENE 
PROMOTERS. 
 
Three replication origins are present at the INK4-ARF locus. Specifically, the 
three mapped replication origins are close to transcriptional start sites of 
p15INK4B and p16INK4A p14ARF genes (Fig. 7) (Dellino et al., 2013).  
 
 
                          
 
Figure 7: The INK4-ARF Locus. Panel a shows the CDKN2A-B locus: the upper line and boxes 
represent the replication origins (ori, black), the exons encoding CDKN2B (p15, green); CDKN2A-
ARF (p14, red) and CDKN2A (p16, blue); the lower line with blue boxes indicates the location of the 
CpG islands. Panel b shows the replication origins (indicated by a green box) mapped in PG and Hela 
cells by I Dellino et al., in Genome Res., 2013 doi: 10.1101/gr.142331.112. 
 
Since CDKN2A-B genes are induced by starvation and repressed when the 
cells enter the cycle (Fig. 5-6) it is possible that the rapid cycles of 
transcription induction-repression (G0-G1) and replication activation (G1-S), 
occurring at the same DNA regions, may generate local DNA damage by 
physical interference between RNA and DNA polymerases. 
To better investigate the consequences of switching on and off p14ARF 
p15INK4B p16INK4A transcription, we performed a Chromatin 
Immunoprecipitation (ChIP) assay with antibodies to phospho-γ-H2aX 
protein (pγ-H2AX), a marker of DNA double strand breaks (Kuo and Yang, 
2008) in HeLa cells subjected to cycles of starvation.  
Fig. 8 shows that pγ-H2AX signal accumulates at the promoter region of 
CDKN2A-B genes selectively when S1 phase begins (Fig. 6). Under the 
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same conditions p2/CDKN1A promoter did not show any evidence of pγ-
H2AX accumulation (Fig. 8). 
 
 
  
  
Figure 8: DNA Damage Signature At CDKN2A-B Promoters. The experiment was performed as 
described in Figure 1. Cells were fixed by paraformaldehyde solution and the chromatin was analyzed 
by ChIP assay using pγH2AX antibody. All primers were designed in order to match the (TSS) 
transcriptional start site region (a range of 1000bp from the coding DNA sequences or CDS). Each 
experiment was performed at least in triplicate. 
 
To obtain an independent evidence of DNA damage under conditions of 2h 
starvation+ 2h serum (2+2), we performed a western blot with anti phospho-
ATM antibodies. The starvation cycles (2+2) induce phospho-ATM and 
confirm the DNA damage found at the CDKN2A-B promoters by pγ-H2AX 
accumulation (Fig. 9). The topoisomerase II inhibitor etoposide was used as 
positive control of DNA damage (Fig.9). 
 
 
 
 
Figure 9: DNA Damage Occurs In Hela  Starved Cells After FBS Administration. Immunoblot 
analysis of  phosphoATM and total ATM in cells exposed to etoposide or starved as indicated at the 
bottom of the gel (A). B shows the quantification of the bands relative to total ATM or to beta actin. 
Each experiment was performed at least in triplicate. 
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4.3 INHIBITION OF DNA POLYMERASE OR OF RNA 
POLYMERASE REDUCES γH2AX ACCUMULATION AT 
CDKN2A/B PROMOTERS 
 
The data shown above suggest that interference of DNA polymerase at the 
onset of S phase with RNA polymerase still engaged at the CDKN2A-B 
promoters, might be the actual cause of DNA damage signatures found under 
conditions of short cycles of starvation and serum stimulation (2+2). If this is 
the case, inhibition of DNA or RNA polymerases should be able to reduce 
significantly pγ-H2AX accumulation. To this end, we performed a chromatin 
immunoprecipitation experiment with pγH2aX antibodies interrogating 
p16INK4A promoter and using two polymerases inhibitors, α-amanitin (Gong 
et al., 2004) and aphidicolin (Sheaff et al., 1991). Fig. 10 shows that during 
starvation there is a significant increase of pγ-H2AX accumulation in cells 
exposed to aphidicolin, whereas under conditions of maximal pγ-H2AX 
accumulation (2+2) both drugs, aphidicolin and  α-amanitin, significantly 
reduced the accumulation of the DNA damage marker. The effects of 
aphidicolin in G0, most likely is due to inhibition of DNA repair in G0 
(Waters, 1981).  It is worth noting that aphidicolin inhibits DNA synthesis 
but does not induce damage per se in the absence of other factors, such as 
oxidative stress (Fig.10) (Venkatachalam et al., 2017). 
 
 
Figure 10: DNA & RNA Polymerase Inhibitors Increase DNA Damage At CDKN2A Promoter. 
The experimental procedure was the same as in figure 3. The inhibitors were present into the media for 
the times indicated. Aphidicolin and α-Amanitin, respectively 1µg/mL and 2,5µM final concentration. 
Each experiment was performed at least in triplicate. 
The treatment with aphidicholin did not reduce the p16INK4A mRNA levels 
following 2 h serum starvation instead it induced it (Fig. 11). α-amanitin 
inhibited, as expected, the accumulation of p16INK4A mRNA in starved cells 
(Fig. 11). 
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Figure 11:  Aphidicholin Does Not Modify The Levels Of CDKN2A mRNA In Starved And Re-
Started Cells. The starvation time and drugs treatments are the same as in Fig.9. Each experiment was 
performed at least in triplicate.  
 
4.4 METHYLATION ASSOCIATED WITH DNA DAMAGE AT 
p16INK4A PROMOTER 
 
 Our previous data indicate that DNA damage and repair are associated with 
de novo DNA methylation (Russo et al., 2016). It is likely that DNA damage 
at  p16INK4A promoter eventually might result in de novo methylation.  
The data shown above demonstrate that rapid cycles of starvation and serum 
re-addition induce DNA damage at p16INK4A gene promoter (Fig. 8). DNA 
damage signatures are reduced by inhibiting DNA or RNA polymerases (Fig. 
10). We repeated the experiment by starving the cells with a same protocol 
(2+2) and measured the extent of DNA methylation by using the anti methyl 
CpG antibody (MeDIP) to immunoprecipitate the p16INK4A promoter DNA. 
Fig. 12 shows that: 1. aphidicholin and a-amanitin increase the methylation 
signal at the p16INK4A promoter under basal conditions. Inhibition of 
transcription reduces methylCpGs turnover due to Tet-hydroxymethylation of 
CpGs (Blattler and Farnham, 2013); 2. 2 h starvation reduces the methylation 
induced by a-amanitin, because  p16INK4A transcription was induced by 
starvation (Fig.5 and 6). The stimulatory effect on methylation by 
aphidicholin in starved cells seems to be a consequence of inhibition of DNA 
repair (Lee et al., 2012). The most striking stimulation of methylation is 
visible in cells that accumulate DNA damage (2+2) (Fig. 8). The cells 
undergoing rapid cycles of starvation and serum stimulation accumulate high 
levels of g-H2AX and increase the CpG methylation signal (Fig. 12). 
Collectively these data support the idea that rapid stimulation of replication 
and transcription cycles facilitates collisions between DNA polymerase 
assembled at initiating replication forks and RNA polymerase recruited to the 
promoter, which happens to be close to a firing replication origin. Eventually, 
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the repair of the double strand break marks the site with de novo methylation 
(Russo et al., 2016). 
 
 
 
Figure 12: Chromatin Immunoprecipitation of p16INK4A Promoter with Anti Methyl CpG 
Antibody In Cells Undergoing Rapid Cycles Of Starvation. MeDIP ChIP of the p16INK4A promoter 
in cells undergoing 2 h starvation and 2 h re-addition of FBS (2+2) in presence and absence of 
aphidicolin and α-amanitin (as described in Fig. 8 and 10). Each experiment was performed in 
triplicate. 
 
4.5 METHYLATED CDKN2A ALLELES IN VIVO EVOLVE DURING 
THE PROGRESSION OF ACUTE MYELOID LEUKEMIA 
The data shown above suggest a link between DNA damage and methylation 
of CDKN2A-B genes. Methylation of suppressor genes in cancer may be a 
consequence of DNA damage generated by DNA and RNA polymerases. 
Since the methylation profiles are stable and heritable, it is likely that 
methylated INK4-ARF alleles are under positive selection pressure and may 
mark successful cancer cells escaping senescence. The analysis of the 
methylation profiles of p16INK4A may provide a window to track the 
progressive evolution of cells harboring dominant oncogene mutations 
Since loss of p16INK4A gene stabilizes leukemogenesis, specifically AML 
(Shields et al., 2016), we decided to analyze the methylation profiles of 
p16INK4A alleles spanning the TSS by deep sequencing of bisulfite DNA 
extracted from bone marrow (BM) or peripheral blood of three AML patients 
(A,B and C) during the disease progression.  All the sequences were 
performed on DNA molecules with identical 5’ and 3’ ends and each 
sequence was representative of a single chromosome. We define these alleles 
that vary only by the location of methylated CpGs, epi-alleles. The 
configuration of several methylated CpGs in a single DNA molecule 
represents the epigenetic equivalent of the haplotype (epi-haplotype). 
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In patient A we found a Single Nucleotide Polymorphism SNP (G/T), which 
has been used to analyze the segregation of methylation with allelic variants.  
Briefly, the methylated alleles differing only by methylation were considered 
epialleles and their frequency analyzed in the total cell population.  
 
 
 
Figure 13: Evolution of  p16INK4A epiallele in the bone marrow cells of  Patient A. The upper inset 
shows the % methylation of each CpG at the 5’ end of p16INK4A gene (35 CpG from -110-to +150 from 
the transcription start site) the arrows indicate the increase of methylation at specific site in the last step 
of our analysis. The histogram shows the methylation of the CpGs in each sample (MID1, grey, MID2 
blue, MID3 red, MID4, green), samples correspond to MDS, AML-1, AzadC and AML-2, which 
represent the different stages of the disease: 1-MDS, (Myelodysplastic syndrome, RAEB I); 2-AML-1 
indicates the progression 1 year after MDS; 3-AzadC indicates the cytological remission of AML-1, 3 
months after therapy with VIDAZA® (75 mg/m2/day subcutaneously for 7 days of a 28-day cycle, 2 
cycles); 4-AML-2 is the final stage of the disease 6 months later (after VIDAZA®). In the segment of 
p16INK4A gene analyzed here, there are 35 CpGs, which have been clustered in 11 groups (the first 
group of CpGs at the 5’ end is marked as 1 and the most 3’ end group is indicated as 11). The color of 
the circles identifies the specific CpGs methylated, while the area of the circles indicates the frequency 
of each epiallele. G or T in each circle indicates the frequency in the specific group of epialleles (color) 
of the SNP G/T found in the p16INK4A segment analyzed. The fraction of blasts present in the sample is 
indicated below the columns along with the fraction of methylated molecules and the date of the 
sample collection. Mono-methylated molecules were excluded from the analysis.  
 
The histogram at the top of Fig. 13 shows the relative frequency of p16INK4A 
epialleles. As shown also by others, the distribution of methylated sites is 
higher at the 5’ and 3’ borders of the nucleosome.  In this specific case, there 
is a nucleosome signature (the first nucleosome from the TSS) centered on 
CpG position 19-20 (data not shown and Hinshelwood et al., 2009 and Wong 
et al., 1999). 
 	 30	
Fig. 13 shows the distribution and the map of the most representative 
epialleles present in the cell population derived from the BM of patient A at 
different stages of the disease. The sequences are shown as circles, the color 
identifies the specific methylated CpGs and the size represents the relative 
frequency of each methylated species in the total population.  
At the onset of the disease, MDS (Fig. 13, first column on the left) classified 
as myelodysplasia (Table I), there are 7 major molecules methylated at the 5’ 
(CpG 1- 6) or 3’ (CpG 9-10) end of the p16INK4A-I exon. The most frequent 
methylated molecules are bi or trimethylated and represent approximately 7 
to 10% of all molecules sequenced (2 to 10K/sample). The G or T alleles 
(SNP) are evenly distributed in the epiallelic groups, indicating that no 
specific selection is applied on this SNP. One year later, MDS evolves into 
AML (AML-1, in Fig. 13) and there is a clear amplification of the epialelles 
seen in M in addition to new variants. The similarity of the CpGs locations 
suggests that new variants originate from previous epialleles that gain 1 or 2 
methyl groups. This is also suggested by net gain of methylated molecules, 
which reach 24% of the total compared to 7% in MDS. Therapy with 
Vidaza® (5- AzadC), DNMT inhibitor, (Fig. 13 III Column, AzadC) 
significantly reduces all the clonal families; 1. it eradicates clones ( 3-4-5, 
green clones) ; 2. it generates new variants (9-10-11) or (1-5-9); 3. it 
amplifies older clones (5-8-11). The last stage of the disease corresponding to 
the relapse, shows a strong positive selection on few clones (Fig. 13, clone 9 
- 10-11) indicating that the disease at this stage is mono or oligoclonal (Fig. 
13, AML-2). The presence of the G/T SNP greatly facilitates the analysis of 
the segregation of the epialelles described and confirms the negative (loss) or 
positive (gain) selection on epialleles during the progression of the disease 
(Fig. 13). The detailed analysis of the association between the SNPs and the 
epialleles shows that few original clones (two or three) generate the entire 
collection of clones that characterize AML-1, AzadC and AML-2 during the 
progression of the disease. Many clones (Fig.13, clone 3, 3-4, 5-8 and 8) 
disappear after the therapy and do not evolve (Fig. 13, Aza-dC sensitive 
clones). Other clones become rampant after the therapy and evolve faster 
than before therapy (Fig. 13, CpG 2-11). This finding is relevant because 5-
AzadC resistant clones were already detectable 6 months before AML-2 (Fig. 
13 lower part) when the fraction of blasts was 5% and clinical phenotype was 
classified as stable remission. 
Since this is a dynamic analysis based on the difference in epiallelic 
frequency, it is important to provide normal or non-evolving controls. To this 
end we analyzed the distribution of p16INK4A epiallele frequency in several 
normal BM controls.  
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Figure 14 shows that the bone marrow of two normal subjects contains 
several p16 epialleles at very low frequency. We did not detect epialleles at 
frequency higher than 0.01% (see below).  
 
 
Figure 14: Frequency And Distribution Of Epialleles Of p16INK4A From bone marrow (BM) Of 
2 Normal Subjects. Similar epialleles are shown by colored circles; color identifies the specific 
methylated CpGs and the area indicates the frequency 
 
This suggests that no selection is applied on cells carrying methylated alleles 
of p16INK4A in the absence of oncogenic mutations.  
To extend our observation, we analyzed p16INK4A epialleles in other 2 
patients (Fig. 15) one with a myelodysplastic syndrome (patient B) and 
another presenting an overt myeloid acute leukemia (patient C).  
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Figure 15: Frequency And Distribution Epialleles p16INK4A in BM Of AML patients (B, upper 
panel and C, lower panel). The upper panel shows the frequency of epialleles in 2 control BMs, N1-
N2 and in the samples of patient B, MDS-1 (myelodysplasia), MDS-2 (3 months after chemotherapy) 
and MDS-2’ (1 year later). The lower panel shows the epiallele frequency in BM samples derived from 
patient C at the onset of the disease (MDS, myelodysplasia) or overt AML-1, after the therapy with 
Vidaza® (azadC) or in relapse (AML-2 and 3), respectively.  
 
As in patient A, we found higher frequency epialleles (Fig. 15) methylated in 
few locations (5’ and 3’ end of the segment analyzed, see Fig. 7a top inset). 
Many epialleles were similar to those in the patient A (Fig. 13 and 15, 
CpG11). The upper panel shows, control BMs (Fig. 15 first 2 columns, N1, 
N2) and 2 stages of the BM of patient B indicated as MDS-1 (Upper panel, 
table II B diagnosis) and MDS-2 after therapy (Upper panel, table III-IV, B, 
remission). The sequence of sample MDS-2’ was repeated 1 year after the 
therapy and no substantial change in the frequency of the major epialleles 
was detected  (Fig. 15, upper panel MDS-2 and MDS-2’).  
The lower panel in Fig. 15 shows the distribution of epialelles in another set 
of samples derived from a third patient (Fig. 15, patient C), which shows a 
dramatic and fast evolution of the epialleles corresponding to the progression 
of the disease. The samples derive from the initial myelodysplasia  (MDS) 
and from overt AML-1, followed by remission after the demethylating 
therapy using Vidaza® (AzadC) and relapse (AML-2 and AML-3). As in 
Fig. 13, there are very similar epialleles that are amplified or hardly 
eliminated by therapy. Also in this case, we notice that therapy facilitates the 
amplification of groups of  epialleles. In the final stage of the disease (AML-
2) 80% of the sequences are represented by 1 clone marked by methylation of 
CpG 11 group. 
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These data demonstrate that these p16INK4A epialleles are not per se the cause 
of the amplification or evolution of the tumor, because similar epialleles are 
present also in not evolving diseases or normal BM (Fig. 15, patient B), but 
their presence confers a selective advantage to founder clones carrying 
oncogenic mutations. Remind that a great fraction of mutated oncogene 
induces senescence, only if p16INK4A is expressed. Since methylation in this 
region of p16INK4A is frequent, the association of these epialelles with 
oncogenic clones occurs at high frequency (Qiu et al., 2011). These clones 
acquire a higher fitness because they exit stably or transiently from 
senescence and become rampant with the time. 
In conclusion, the analysis of p16INK4A epialleles in vivo longitudinally in the 
same patient shows that the p16INK4A epialleles evolve in the 2 AML patients, 
but not in normal controls. In control samples there are many methylation 
profiles corresponding to a large variety of epialleles, but their frequency is 
stable overtime. Also, we wish to note that in patient B the analysis of the 
epialleles shows that disease (MDS) did not progress and stabilized overtime 
(Fig. 15, upper panel). 
We conclude that the qualitative analysis of methylation profiles p16INK4A 
epialleles genes not only describes accurately the evolution of AML but can 
be used to track specific clones and, ultimately, predict chemoresistance. 
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5. DISCUSSION 
5.1 MOLECOLAR COLLISIONS BETWEEN REPLICATION AND 
TRANSCRIPTION MACHINES ARE SOURCES OF DNA DAMAGE 
 
Everyday, cells are subjected to lesions from exogenous and endogenous 
sources: continuous exposure of the cells to DNA damaging agents induces 
degenerative changes and rapid aging. Products of cellular metabolism are 
also able to induce DNA damage that affects cell fitness similarly to the 
effects of common environmental agents, such as UV, ionizing radiations or 
natural/man-made genotoxic chemicals. 
The endogenous sources of DNA mutations derive from errors of replication 
and DNA repair (see for comments Tomasetti et al., 2017). Also, Interference 
and conflicts between DNA replication and transcription machines, in terms 
of molecular collisions, has been described in bacteria as potential cause of 
DSB (French, 1992) (Liu and Alberts, 1995). 
In the context of collisions between DNA and RNA polymerases, it is 
possible to describe two different scenarios: co-directional and head-on 
collision. 
 
 
Figure 16: Schematic Representation Of Collision Between DNA And RNA Polymerase 
Complexes In Bacteria. (a) Co-directional collision occurs when a gene is encoded on the leading 
strand. (b) Head-on collision occurs when a gene is encoded on the lagging strand. 
Adapted from Chen; 2013; doi: 10.1093/gbe/evt193. 
 
The difference in speed of DNA and RNA polymerase in bacteria (Rocha and 
Danchin, 2003) generates co-directional collisions when the enzymes are 
working on the leading strand (Fig. 16 a). If the genes are highly transcribed 
(Merrikh et al., 2011), they became hotspots of co-directional conflicts.  If a 
nick is present on the transcribed strand, DNA polymerase will stop and a 
DSB will be generated. Repair of the site by HR may leave methylated sites 
on the template strand (Russo et al., 2016). 
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On the other hand, when a gene is encoded on the lagging strand, head-on 
collisions occur  (Fig. 16 b) (Chen and Zhang, 2013). The head-on collisions 
translate in a stop of replication fork progression and replication stress 
(Merrikh et al., 2011). Pause of replication fork (RFP) by head-on collisions 
is associated, in mammalian cells, with increase of HR activity at that site 
(Prado and Aguilera, 2005) in order to prevent genomic instability. The 
regions of RFP coupled to DNA break formation are known as common 
fragile sites (CFS) (Helmrich et al., 2011). Also, in these cases HR leaves 
methylation marks on the repaired segment (Cuozzo et al., 2017; Morano et 
al., 2014). 
 
5.2 DNA DAMAGE AND DNA METHYLATION 
 
The relation between DNA damage, repair and DNA methylation seems well 
established. DNA methyltrasferase-I and IIIa-b enzymes are implicated in 
DNA damage, repair and methylation. DNMT1 is found associated with 
proliferating cell nuclear antigen (PCNA) during replication and repair 
(Chuang et al., 1997), and it is required to prevent genomic instability (Chen 
et al., 1998). How these events were temporally related was discovered later. 
C. Cuozzo et al. in 2007 and G. Russo et al. in 2016, using the DRGFP 
plasmid developed by M.Jasin (Pierce et al., 1999), demonstrated that DSB 
and HR induce early transient and stable inheritable changes of local 
chromatin. Local DNA methylation is essential to stabilize the chromatin 
changes induced by DSB and HR and transcription also reshapes local DNA 
methylation following damage and HR. Together, DNA damage and 
transcription may be ultimately responsible for the high degree of 
polymorphism of somatic methylation. DNA damage increases in 
hyperplastic precancerous cells and precedes genomic instability and loss of 
p53 expression in many tumors (Gorgoulis et al., 2005). Repair of the lesions 
by HR and methylation generate a pool of cells with different levels of 
expression of the repaired gene and depending on the function of the gene 
(oncosuppressor genes, for example) de novo DNA methylation induced by 
damage and repair can confer a inheritable selective advantage. 
 
5.3 METHYLATION OF CDKN2A-B SUPPRESSOR GENES IS A 
FREQUENT EVENT DURING NEOPLASTIC PROGRESSION 
 
Silencing of CDKN2A-B suppressor genes is a very frequent event during 
cancer progression. In fact, the expression of these genes, in cells carrying 
dominant oncogene mutations, induces senescence (Bianchi-Smiraglia and 
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Nikiforov, 2012). Methylation of DNA may be an important cause of 
silencing, but is not known what kind of event leads to gene silencing. 
Two different models have been proposed. An epigenetic change, such as 
promoter CpG island hypermethylatyon, can occur randomly at the site of 
DNA damage. If this modification modifies gene expression then a selective 
advantage for the modified cell will be forwarded to daughter cells (Hassler 
and Egger, 2012). This model is essentially stochastic because the DNA 
modified site is random. 
A determinist event, on the contrary, leading to methylation of a specific 
DNA segment can be induced by oncogene-activated transcriptional factors 
targeting at the specific site the, de novo methyl transferases, DNMT3a or b. 
There are many examples of oncogenic proteins able to induce silencing of 
oncosoppressor genes, for example K-RAS. K-RAS directed signalling in 
colorectal cancer cells switches off INK4-ARF genes. The oncogene 
activates a zinc finger protein ZNF304 that recruits at the promoters of INK4-
ARF genes DNMT1. Targeted DNMT1 induces inheritable local methylation 
and repression of transcription (Serra et al., 2014).  
Other oncogenic proteins can trigger similar pathways, for example Myc in 
lymphoma T cells (Opavsky et al., 2007).  
The data presented here support both models because DNA methylation is 
dependent on damage and transcription. The activation or stimulation of 
transcription and replication are essentially deterministic events because they 
are induced by specific proteins and factors that recognize specific sequences 
in the genome; on the other hand, the DNA damage induced at TSS by 
interference between transcription and replication is stochastic because it 
depends on the timing and on the chances that DNA and RNA polymerases 
are present and travelling on the same strand. The stochastic component of 
methylation is also highlighted by the high polymorphism, which is cell and 
individual specific.  
 
5.4 DNA METHYLATION AS BAR-CODE TO IDENTIFY AND 
TRACK SPECIFIC EPIALLELES 
 
The data presented here highlight the variability and the polymorphism of p16INK4A methylated alleles (epialleles). The polymorphism of CpG at TSS of p16INK4A can be detected and measured because deep sequencing of bisulfite-
treated DNA was performed on single DNA molecules with the same 5’ and 
3’ ends. In complex populations of cells, such as those found in BM or blood 
from AML patients, the number of different epialleles in the population 
defines the frequency and the degree of the methylation-polymorphism (epi-
polymorphism). The combination of different epiallele families in an 
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individual DNA sample can be represented as a bar code that characterizes 
the individual DNA. During the progression of AML in the 2 patients we 
have documented changes in the frequency of p16INK4A epialleles, which 
reflect positive and negative selection exerted on families of epialleles by 
genetic and epigenetic changes. For example, the demethylating therapy 
amplified some families of epialleles and reduced others. This conclusion can 
be drawn only by the analysis of the frequency overtime of each epiallele 
family (Fig. 13-15). Ultimately, the epigenetic distance between epialleles 
can be calculated as the difference in methyl CpG location in pairs of 
samples and the appearance of successful clones can be detected by 
computing the frequency of epiallele families overtime. 
 
5.5 QUANTITATIVE VS QUALITATIVE DNA METHYLATION 
ANALYSIS  
 
Nowadays, the limit of the analysis of changes in DNA methylation status 
and their relationship with cancer progression is due to the lower coverage 
and to the quantitative assessment of each methylated CpG.  The population 
of bisulfite resistant CpGs does not allow the analysis of single DNA 
molecules. Pyrosequencing highlights the statistical occurrence of single 
methylated CpGs in the majority of molecules, but doe not allow the analysis 
of single molecules with different location of methylated CpGs. These 
moelcules are described as epialleles similarly to alleles defined by SNPs. 
We have applied the same analysis of SNPs to methylCpGs. This approach 
provides information on alleles differing only by location of methylated 
CpGs (see Florio et al., 2017). 
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Figure 17: Schematic Representation Of Quantitative VS Qualitative Methylation Analysis Of 
Epialleles. In the figure 4 GpG are performed by (on the left side) a quantitative and (on the right 
side) a qualitative analysis where U= un-methylated F= fully-methylated I= intermediate.  
Adapted from Florio; 2017; 10.1080/15592294.2016.1260211 
 
As shown in Fig. 17, the quantitative approach overlooks the heterogeneity of 
a population dividing it only into two major groups of epialleles, while the 
qualitative analysis allows the identification of families of epialleles and 
greatly reduces the heterogeneity of methylation. Since cancer cells are 
highly heterogeneous (Gay et al., 2016), this type of qualitative analysis of 
methylation applied to a complex population of cells can reduce 
heterogeneity and identify clones. 
The analysis of p16INK4A epialleles in AML reported here shows that the 
heterogeneity of epialleles is only apparent because we can identify and tarck 
the same clones overtime during the progression of the disease. 
The presence/absence of epialleles and their increase/decrease of frequency 
after a treatment give to us an estimation of the efficiency of the treatment 
and eventually suggest us to move to other drugs.      
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6. CONCLUSIONS 
 
The methylation of the promoter of oncosoppressor genes is a common event 
during cancer progression and the data presented here provide a possible 
explanation of the molecular mechanism underlying gene silencing. 
Progressive CpG methylation at p16INK4A promoter region is a direct 
consequence of endogenous damage. p16INK4A silenced cells overcome the 
senescence barrier and increase the fitness overtime. The progressive 
accumulation of methyl groups at the TSS of p16INK4A further improves the 
fitness of cell clones and favors the neoplastic progression. In vivo we 
identify several epialleles of p16INK4A gene and overtime in 2 cases of AML 
we document a selective amplification of certain types of epialleles, which 
are resistant to the demethylating therapy and are further amplified at the 
disease relapse. 
These data offer an explanation for cancer heterogeneity, but especially 
provide an effective and precise approach to monitor the patients during the 
therapy.    
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